Trastuzumab Emtansine
Antibody–drug conjugate
Evidence outlook
Approved: HER2-Positive Breast Cancer, Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
von Minckwitz et al. (N Engl J Med, 2019; PMID 30516102) report different figures for this outcome from the interim analysis: 3-year invasive disease-free survival of 88.3% with T-DM1 and 77.0% with trastuzumab (hazard ratio 0.50).
track record: Partial signal
Also approved (2)
- Early Breast Cancer (EBC) Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Metastatic Breast Cancer (MBC) Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy...
- Treatment of unresectable or recurrent HER2- positive breast cancer
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01772472 NCT01772472 · HER2-Positive Breast Cancer This was a large randomized active-controlled trial with 743 participants per arm and a hard clinical endpoint, invasive disease-free survival. The primary endpoint was met, with 3-year invasive disease-free survival of 88.44% versus 77.12% for trastuzumab emtansine and trastuzumab, respectively (hazard ratio 0.54; p<0.0001), but treatment assignment was not blinded. von Minckwitz et al. (N Engl J Med, 2019; PMID 30516102) report different figures for this outcome from the interim analysis: 3-year invasive disease-free survival of 88.3% with T-DM1 and 77.0% with trastuzumab (hazard ratio 0.50). Registry: NCT01772472 | 3 | Invasive Disease-free Survival (IDFS) Rate at 3 Years (At Year 3) 2018-07-25 | Invasive Disease-free Survival (IDFS) Rate at 3 Years (At Year 3): Trastuzumab 77.12 percentage of participants (95% CI 73.96 to 80.28) | Trastuzumab Emtansine 88.44 percentage of participants (95% CI 86.07 to 90.81) | Partial signal | link ↗ |
View 3 more trials
NCT01419197 NCT01419197 · HER2-Positive Breast Cancer The trial was adequately sized and randomized, with an active physician-choice comparator, but it was open-label rather than double-blinded. Both co-primary clinical endpoints were met statistically: progression-free survival and overall survival favored trastuzumab emtansine, so the results are meaningful, while the lack of blinding limits the design strength. Registry: NCT01419197 | 3 | Progression-free Survival (Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)); Overall Survival (Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)) 2013-02 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02131064 NCT02131064 · HER2-Positive Breast Cancer The trial was randomized and actively controlled, with 221 participants receiving chemotherapy plus trastuzumab and pertuzumab and 223 receiving trastuzumab emtansine plus pertuzumab, but treatment was open-label rather than blinded. Its hard primary endpoint, pathological complete response at surgery, was not met for trastuzumab emtansine: 44.4% versus 56.1% with the comparator (p=0.0126), favoring the chemotherapy regimen. Hurvitz et al. (Lancet Oncol, 2018; PMID 29175149) report different figures for this outcome: pathological complete response in 99 of 223 patients (44.4%) with T-DM1 plus pertuzumab and 123 of 221 (55.7%) with chemotherapy plus trastuzumab and pertuzumab (difference -11.3 percentage points, p=0.016). Registry: NCT02131064 | 3 | Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples (Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months)) 2015-12-31 | Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples (Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months)): TCH + P 56.1 Percentage of Participants (95% CI 49.29 to 62.76) | T-DM1 + P 44.4 Percentage of Participants (95% CI 37.76 to 51.18) | Partial signal | link ↗ |
NCT00829166 NCT00829166 · Breast Cancer The trial was randomized and compared trastuzumab emtansine with active treatment in 991 participants, using objective clinical endpoints; its co-primary progression-free survival and overall survival comparisons both favored trastuzumab emtansine with statistically significant results. However, it was open-label and no power calculation is reported in the provided sources, so the evidence is rated moderate rather than strong. Registry: NCT00829166 | 3 | Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC) (From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)); Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint) (From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)); Percentage of Participants Who Died: Second Interim Analysis (From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)); Overall Survival: Second Interim Analysis (Co-primary Endpoint) (From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)); Percentage of Participants Who Died: Final Analysis (From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)); Overall Survival: Final Analysis (From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)); Percentage of Participants Who Were Alive at Year 1; Percentage of Participants Who Were Alive at Year 2 2012-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (55)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Used as active comparator (11)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Appears in other studies (8)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Trastuzumab Emtansine: this drug | Approved | Antibody–drug conjugate | HER2 (ERBB2) | Partial signal | Featured results are non-efficacy only in this race | |
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | Reliable signal | NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5) | |
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | Reliable signal | NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36) | |
| Camizestrant (Etcamah) | Approved | Small molecule | Estrogen receptor | Reliable signal | NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) | |
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | Reliable signal | NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7) NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed | |
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | Partial signal | NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) | |
| Elacestrant | Approved | Small molecule | Estrogen receptor | Partial signal | NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) | |
| Epirubicin | Approved | Small molecule | Topoisomerase II / DNA | Partial signal | NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed | |
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | Partial signal | NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | Partial signal | NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164) NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14) | |
| Exemestane | Approved | Small molecule | Aromatase | Reliable signal | NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88) NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86). | |
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | Partial signal | NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010). | |
| Gedatolisib (Revtorpyk) | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | Partial signal | NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001. | |
| Imlunestrant (Inluriyo) | Approved | Small molecule | Estrogen receptor | Partial signal | NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 | |
| Inavolisib (Itovebi) | Approved | Small molecule | PI3K-alpha | Reliable signal | NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3) | |
| Ixabepilone | Approved | Small molecule | Microtubules (tubulin) | Partial signal | Featured results are non-efficacy only in this race | |
| Margetuximab (Margenza) | Approved | Monoclonal antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Nab-Paclitaxel | Approved | Small molecule | Microtubules | Partial signal | NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed | |
| Neratinib | Approved | Small molecule | EGFR/HER2 | Reliable signal | NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4) | |
| Olaparib | Approved | Small molecule | PARP | Partial signal | NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3) NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17) | |
| Palbociclib (Ibrance) | Approved | Small molecule | CDK4 and CDK6 | Reliable signal | NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1) | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pertuzumab | Approved | Monoclonal antibody | HER2/neu Receptor Antagonist | Partial signal | NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016). NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results). | |
| Ribociclib | Approved | Small molecule | CDK4 and CDK6 | Reliable signal | NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4) | |
| Sacituzumab Govitecan | Approved | Antibody–drug conjugate | TROP2 | Partial signal | NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6) | |
| Talazoparib | Approved | Small molecule | PARP | Partial signal | NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7) | |
| Tamoxifen (Soltamox) | Approved | Small molecule | Estrogen receptor | not yet graded | NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending | |
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | Partial signal | NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1) | |
| Tucatinib | Approved | Small molecule | HER2 | Reliable signal | NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1) | |
| Vepdegestrant (Veppanu) | Approved | Small molecule | Estrogen receptor | Partial signal | NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41) | |
| BEBT-209 | Phase 3 | Small molecule | CDK4 (selective) | not yet graded | No reviewed efficacy summary in this indication | |
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Patritumab Deruxtecan | Phase 3 | Antibody–drug conjugate | HER3 | Weak signal | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | Partial signal | NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| (Z)-Endoxifen | Phase 2 | Small molecule | Estrogen receptor (antagonist) | Partial signal | NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001. | |
| JS207 | Phase 2 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Tersolisib | Phase 2 | Small molecule | PI3K-alpha (mutant-selective, allosteric) | not yet graded | No reviewed efficacy summary in this indication | |
| ECI830 | Phase 1/2 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| GVV858 | Phase 1/2 | — | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-2189 | Phase 1/2 | Undisclosed | KAT6A / KAT6B | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-6208 | Phase 1/2 | Undisclosed | CDK7 | not yet graded | No reviewed efficacy summary in this indication | |
| Tegtociclib | Phase 1/2 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| IEV407 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-101684362 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| RAE346 | —(overall) | Small molecule | PI3Kα (mutant-selective) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trastuzumab Emtansine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.